Dr. Christos Sotiriou presents new insights on lobular breast cancer at SABCS 2025, outlining four biologically distinct subtypes with potential clinical implications and highlighting data suggesting that PI3K inhibitors may benefit lobular tumors by targeting both cancer cells and the tumor microenvironment.
